ToffCap’s Monday Monitor #75LAVA Therapeutics N.V. – LVTX
Pitch Summary: LAVA Therapeutics is being acquired by XOMA, with a cash offer and a contingent value right (CVR) that could be significantly undervalued, offering substantial upside potential. BSD Analysis: The acquisition of LAVA Therapeutics by XOMA includes a cash offer of $1.16 per share and a CVR that provides holders with a share of […]
